Today, CRISPR Therapeutics AG Common Shares’ Quiet Period To End Tomorrow (NASDAQ:CRSP)

Today, CRISPR Therapeutics AG Common Shares’ Quiet Period To End Tomorrow (NASDAQ:CRSP)

CRISPR Therapeutics AG Common Shares’ (NASDAQ:CRSP) quiet period is set to expire on Monday, November 28th. CRISPR Therapeutics AG Common Shares had issued 4,000,000 shares in its public offering on October 19th. The total size of the offering was $56,000,000 based on an initial share price of $14.00. During CRISPR Therapeutics AG Common Shares’ quiet period, underwriters and any insiders that worked on the IPO are restricted from issuing any research reports for the company because of SEC regulations. Following the expiration of the company’s quiet period, the brokerages that served as underwriters will likely initiate research coverage on the company.

A number of research analysts recently weighed in on the company. Citigroup Inc. assumed coverage on CRISPR Therapeutics AG Common Shares in a report on Tuesday, November 15th. They issued a “neutral” rating and a $19.00 target price on the stock. Guggenheim assumed coverage on CRISPR Therapeutics AG Common Shares in a report on Monday, November 14th. They issued a “buy” rating and a $30.00 target price on the stock. Piper Jaffray Cos. assumed coverage on CRISPR Therapeutics AG Common Shares in a report on Monday, November 14th. They issued an “overweight” rating and a $21.00 target price on the stock. Finally, Barclays PLC assumed coverage on CRISPR Therapeutics AG Common Shares in a report on Monday, November 14th. They issued an “overweight” rating and a $22.00 target price on the stock.

CRISPR Therapeutics AG Common Shares (NASDAQ:CRSP) opened at 20.40 on Friday. The firm has a 50-day moving average price of $17.10 and a 200 day moving average price of $17.10. The stock’s market capitalization is $107.34 million. CRISPR Therapeutics AG Common Shares has a 52-week low of $13.75 and a 52-week high of $23.97.

In related news, major shareholder Corp /De/ Celgene purchased 800,150 shares of the company’s stock in a transaction on Monday, October 24th. The shares were bought at an average price of $14.00 per share, with a total value of $11,202,100.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, Director Simeon George bought 66,500 shares of the business’s stock in a transaction on Monday, October 24th. The shares were purchased at an average cost of $14.00 per share, for a total transaction of $931,000.00. The disclosure for this purchase can be found here.

Related posts

Leave a Comment